SCHEMBL20041851

SCHEMBL20041851

COc1ccc([C@H]2CC(=O)NC2C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.47
MAOA P21397 2/20 0.47
MAOB P27338 1/20 0.47
MAP2K1 Q02750 1/20 0.46
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
KDM4E B2RXH2 2/20 0.44
GAA P10253 2/20 0.44
CYP3A4 P08684 1/20 0.42
FPR1 P21462 3/20 0.42
FPR2 P25090 1/20 0.42
HTR2C P28335 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20041901 1.00 KDM1A (0.47) KDM1AMAOAMAOBMAP2K1DDB1
SCHEMBL19559429 1.00 KDM1A (0.47) KDM1AMAOAMAOBMAP2K1DDB1
SCHEMBL18590503 0.81 MAPT (0.42) CYP3A4HTR2CALDH1A1SMN1; SMN2MEN1
SCHEMBL18590502 0.81 MAPT (0.42) CYP3A4HTR2CALDH1A1SMN1; SMN2MEN1
SCHEMBL18590508 0.81 MAPT (0.42) CYP3A4HTR2CALDH1A1SMN1; SMN2MEN1
SCHEMBL18590507 0.81 MAPT (0.42) CYP3A4HTR2CALDH1A1SMN1; SMN2MEN1
SCHEMBL6482507 0.79 SLC6A3 (0.45) GAAFPR1FPR2ALDH1A1TP53
SCHEMBL6482502 0.79 SLC6A3 (0.45) GAAFPR1FPR2ALDH1A1TP53
SCHEMBL6482499 0.79 SLC6A3 (0.45) GAAFPR1FPR2ALDH1A1TP53
SCHEMBL1901694 0.79 ALDH1A1 (0.48) MAOAMAOBGAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3305763-A1 DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS Kyorin Pharmaceutical Co., Ltd. (JP) 2018-04-11 EP disclosed